Harmony Biosciences Holdings, Inc. (HRMY) Stock
7 of the hedge funds AlphaScala tracks reported HRMY in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Renaissance Technologies's at $43.52M. Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
Which hedge funds own HRMY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 1.20M | $43.52M | +11% |
| Millennium Management Israel Englander | 320K | $11.64M | -66% |
| Citadel Ken Griffin | 256K | $9.31M | -56% |
| Bridgewater Associates Ray Dalio | 249K | $9.05M | -1% |
| Marshall Wace | 160K | $5.82M | +7% |
| D.E. Shaw David Shaw | 53K | $1.93M | -48% |
| Hussman Investment Trust John Hussman | 32K | $1.24M | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Harmony Biosciences Holdings, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 18, 26 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 35.9K | $1.5M |
| Sep 17, 26 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 800 | $34K |
| Sep 16, 26 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 1.8K | $77K |
| Sep 8, 26 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 4.5K | $190K |
| Sep 8, 26 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 1.0K | $43K |
| Sep 8, 26 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 23.0K | $989K |
| Sep 4, 26 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 5.5K | $231K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →HRMY price chart
Powered by TradingViewWhat does Harmony Biosciences Holdings, Inc. do?
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on the development and commercialization of therapies for neurological disorders. Its lead product, WAKIX, is a molecule with a novel mechanism of action that increases histamine signaling in the brain by binding to H3 receptors, primarily targeting conditions such as narcolepsy and cataplexy. The company operates in the health technology sector, specifically within pharmaceuticals, providing treatments that address unmet needs in sleep-wake disorders and related neurological conditions. WAKIX has received approvals for expanded indications, including cataplexy in pediatric patients, broadening its therapeutic reach. Harmony Biosciences Holdings, Inc. emphasizes innovative solutions in this specialized market, supporting patients through targeted pharmacotherapies. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company plays a key role in advancing treatments for rare and debilitating neurological diseases.